Bering Partners II, L.P. disclosed a 6.9% stake in CalciMedica, Inc. common stock. The Schedule 13D was filed on Jul. 02, 2026 after the fund bought 1,450,267 units in CalciMedica’s June 25 private placement. The move shifts their prior 13G to a 13D and follows an increase to a 19.99% warrant ownership cap, signaling room to act.
Investor Intent
Bering Partners II bought 1,450,267 units at $0.8033 per unit on June 25, receiving common shares now and rights to Series A and Series B warrants once stockholders approve them. The fund also holds a 2024 warrant that it kept active through Dec. 31, 2026, and on Jul. 2 it raised that warrant’s ownership cap to 19.99%.
Both the new Series A and Series B warrants include a similar limit: “may not be exercised if the aggregate number of shares…would exceed…19.99%.” The fund says it holds the position for investment and may buy more or sell shares as conditions evolve.
Investor's Background
Bering Partners II, L.P. is a Delaware limited partnership and venture capital investment entity managed by Bering Partners II GP, L.L.C. The firm is led by managing members Evgeny Zaytsev and Philip Sawyer and invests in companies for capital appreciation. Zaytsev serves on CalciMedica’s board, providing board-level visibility into the business.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.